Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, Journal Year: 2024, Volume and Issue: 1871(3), P. 167647 - 167647
Published: Dec. 30, 2024
Language: Английский
Cancers, Journal Year: 2024, Volume and Issue: 16(17), P. 2975 - 2975
Published: Aug. 27, 2024
Malignant gliomas present great difficulties in treatment, with little change over the past 30 years median survival time of 15 months. Current treatment options include surgery, radiotherapy (RT), and chemotherapy. New therapies aimed at suppressing formation new vasculature (antiangiogenic treatments) or destroying formed tumor (vascular disrupting agents) show promise. This study summarizes existing knowledge regarding processes by which glioblastoma (GBM) tumors acquire resistance to antiangiogenic treatments. The discussion encompasses activation redundant proangiogenic pathways, heightened cell invasion metastasis, induced hypoxia, creation vascular mimicry channels, regulation immune microenvironment. Subsequently, we explore potential strategies overcome this resistance, such as combining other methods, personalizing treatments for each patient, focusing on therapeutic targets, incorporating immunotherapy, utilizing drug delivery systems based nanoparticles. Additionally, would like discuss limitations methods future directions enhance beneficial effects patients GBM. Therefore, review aims research outcome GBM provide a more promising opportunity thoroughly exploring mechanisms investigating novel strategies.
Language: Английский
Citations
10
Biomedicines, Journal Year: 2025, Volume and Issue: 13(1), P. 133 - 133
Published: Jan. 8, 2025
Glioblastoma is one of the most aggressive brain cancers, characterized by active infiltrative growth and high resistance to radiotherapy chemotherapy. Sesquiterpene triterpenoids (STLs) their semi-synthetic analogs are considered as a promising source novel anti-tumor agents due low systemic toxicity multi-target pharmacological effects on key processes associated with tumor progression. The current review aims systematize knowledge anti-glioblastoma potential STLs accumulated over last decade identify in glioblastoma cells that susceptible action STLs. An analysis published data clearly demonstrated STLs, which can successfully cross blood-brain barrier, exert complex inhibitory effect through induction "mitochondrial dysfunction-oxidative stress-apoptosis" axis, inhibition glucose metabolism cell cycle phase transition, suppression motility invasion blockade proneural-mesenchymal transition. Taken together, this highlights not only able induce death, but also effectively affect diffusive spread, suggests possible directions for further investigation context better understand mechanism action.
Language: Английский
Citations
0
Frontiers in Cell and Developmental Biology, Journal Year: 2025, Volume and Issue: 13
Published: Feb. 26, 2025
Glioblastoma (GBM) is one of the deadliest tumors due to its high aggressiveness and resistance standard therapies, resulting in a dismal prognosis. This lethal tumor carries out metabolic reprogramming order modulate specific pathways, providing metabolites that promote GBM cells proliferation limit efficacy treatments. Indeed, remodels glucose metabolism undergoes Warburg effect, fuelling glycolysis even when oxygen available. Moreover, recent evidence revealed rewiring nucleotide, lipid iron metabolism, not only an increased growth, but also radio- chemo-resistance. Thus, while on hand advantage for GBM, other it may represent exploitable target hamper progression. Lately, number studies focused drugs targeting uncover their effects therapy resistance, demonstrating some these are effective, combination with conventional treatments, sensitizing radiotherapy chemotherapy. However, heterogeneity could lead plethora alterations among subtypes, hence treatment might be effective proneural mesenchymal ones, which more aggressive resistant approaches. review explores key mechanisms involvement highlighting how acts as double-edged sword taking into account pathways seem offer promising options GBM.
Language: Английский
Citations
0
Cancer Letters, Journal Year: 2025, Volume and Issue: unknown, P. 217601 - 217601
Published: March 1, 2025
Language: Английский
Citations
0
International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(6), P. 2763 - 2763
Published: March 19, 2025
Glioblastomas (GBMs), among the most aggressive and resilient brain tumors, characteristically exhibit high angiogenic potential, leading to formation of a dense yet aberrant vasculature, both morphologically functionally. With these premises, numerous expectations were initially placed on anti-angiogenic therapies, soon dashed by their limited efficacy in concretely improving patient outcomes. Neovascularization GBM emerged as complex, dynamic, heterogeneous process, hard manage with classical standard care. Growing evidence has revealed existence non-canonical strategies angiogenesis, variously exploited meet its ever-increasing metabolic demand differently involved tumor progression, recurrence, escape from treatments. In this review, we provide an accurate description each neovascularization mode encountered tumors date, highlighting molecular players signaling cascades primarily involved. We also detail key architectural functional aspects characteristic vascular compartment because intricate crosstalk between different networks. Additionally, explore repertoire emerging therapies against that are currently under study, concluding question: faced such challenging scenario, could combined tailored patient’s genetic signatures, represent effective game changer?
Language: Английский
Citations
0
Results in Chemistry, Journal Year: 2024, Volume and Issue: 9, P. 101645 - 101645
Published: July 1, 2024
Glioblastoma is an aggressive brain tumor with high mortality and a median survival of about 15 months. Starting from our previous published compound, MV1035 that inhibited migration invasiveness glioblastoma U87 cells, also exhibited synergic effect in combination the alkylating agent Temozolomide, we identified new active molecules, aim to understand key motifs responsible for activity against DNA repair protein ALKBH2 RNA demethylase ALKBH5. We modified original structure MV1035, synthesizing molecules have been tested through MTT assay, cell-free assay ALKBH5 assay. found compound 6 able reduce both obtained important information these inhibitors. However, considering complexity, heterogeneity plasticity GBM GSC will need be validated vivo.
Language: Английский
Citations
2
International Immunopharmacology, Journal Year: 2024, Volume and Issue: 143, P. 113573 - 113573
Published: Nov. 7, 2024
Language: Английский
Citations
1
Biomedicines, Journal Year: 2024, Volume and Issue: 12(10), P. 2236 - 2236
Published: Oct. 1, 2024
The intrinsic molecular heterogeneity of glioblastoma (GBM) is one the main reasons for its resistance to conventional treatment. Mesenchymal GBM niches are associated with hypoxic signatures and a negative influence on patients' prognosis. To date, competing endogenous RNA (ceRNA) networks have been shown broad impact progression various cancers. In this study, we decided construct hypoxia-specific microRNA/ messengerRNA (miRNA/mRNA) putative circular (circRNA) regulatory component using available bioinformatics tools.
Language: Английский
Citations
0
Current Issues in Pharmacy and Medical Sciences, Journal Year: 2024, Volume and Issue: 37(4), P. 216 - 220
Published: Nov. 28, 2024
Abstract SARS-CoV-2 infection often causes neurological disorders. Experimental studies on an animal model have shown that is able to cross the blood-brain barrier. Researchers also discovered can infect glial cells. Gliomas are most common type of brain tumor. Oncological patients at high risk infections, including SARS-CoV-2. Moreover, their weakened immunity level antibodies after or vaccination be lower than in healthy population. Therefore, aim our study was evaluate occurrence RNA tumor tissue collected during surgery. We tested anti-SARS-CoV-2 these patients. The obtained results indicate tropism virus – glioblastoma. anti-SARS higher with detected tumour tissue.
Language: Английский
Citations
0
Heliyon, Journal Year: 2024, Volume and Issue: 11(1), P. e41440 - e41440
Published: Dec. 24, 2024
Gliomas are the most common primary tumors of nervous system, which is generally treated using adjuvant chemotherapy following surgical resection. However, patient survival time still short, and there currently no successful treatment for highly malignant gliomas. Bullatine A (BLA) a diterpenoid alkaloid genus Aconitum antirheumatic anti-inflammatory pharmacological properties. The effects BLA on gliomas have not yet been elucidated. In this study, we investigated human brain glioblastoma cells. Our results showed that inhibited proliferation U87MG U251 cells in dose-dependent manner decreased their rate. dose-dependently induced apoptosis cells, upregulated expression cleaved caspase-9, caspase-3 pro-apoptotic protein, Bax downregulated Bcl-2 anti-apoptotic protein. Moreover, cell cycle arrest G2/M phase, p-ERK Myc proteins. Further, significantly acetylation histones H3K9 H3K56, protein deacetylase SIRT6. Mechanistic studies revealed effect inducing inhibiting glioma was blocked by SIRT6 knockout. summary, our study indicated potential therapeutic agent targets to inhibit induce apoptosis.
Language: Английский
Citations
0